Treatment of the Raynaud's phenomenon with piracetam.
Piracetam (Nootropil, CAS 7491-74-9) has been investigated in the treatment of primary and secondary Raynaud's phenomenon in three sequential and complementary studies.
Lavenne-Pardonge, E. +4 more
core
We investigated the effects of piracetam, a nootropic, on learning and memory formation for a passive avoidance task in day-old chicks. To test for the possible cognitive-enhancing properties of piracetam, a weak learning version of this task--whereby ...
Daisley, Jonathan N. +7 more
core +1 more source
Positive Experiences With Piracetam [PDF]
openaire +2 more sources
The Citrus Flavonoid Naringin Confers Neuroprotection Against Cerebral Ischemia by Enhancing Endogenous Antioxidant Capacity and Suppressing Neuroinflammation. [PDF]
Kongsui R +4 more
europepmc +1 more source
A Staged Translational Framework for Evaluating Oral Glutamatergic and Senescence-Modulating Strategies in Treatment-Resistant Depression. [PDF]
Cheung N.
europepmc +1 more source
The effects of Piracetam, Naftidrofuryl and methamphetamine on several parameters of cerebral energy metabolism have been studied. At variance with some reports in the literature neither Piracetam nor Naftidrofuryl affected the cerebral contents of ...
Nickolson, V.J., Wolthuis, O.L.
core
Differential Improvement in Obsessive Rumination and Fantasy Intrusions Versus Attachment-Related Emotional Dysregulation During Oral Glutamatergic Augmentation in a 16-Year-Old Adolescent. [PDF]
Cheung HK, Cheung N.
europepmc +1 more source
Optimized Oral Glutamatergic Augmentation in Refractory Home-Dominant Contamination Obsessive-Compulsive Disorder With Somatic, Affective, and Motivational Features: A Case Report of Incremental Functional Gains. [PDF]
Cheung HK, Cheung N.
europepmc +1 more source

